13G Filing: Foresite Capital Fund III, L.P. and Cymabay Therapeutics Inc. (CBAY)

Page 2 of 11

Page 2 of 11 – SEC Filing

1 NAME OF REPORTING PERSONS         Foresite Capital Fund III, L.P. (“FCF III”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)         ¨         (b)         x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING

PERSON
WITH

5 SOLE VOTING POWER
600,000 shares, except that Foresite Capital Management III, LLC (“FCM III”), the general partner of FCF III, may be deemed to have sole power to vote these shares, and James Tananbaum (“Tananbaum”), the managing member of FCM III, may be deemed to have sole power to vote these shares.
6 SHARED VOTING POWER
See response to row 5.
7

SOLE DISPOSITIVE POWER

600,000 shares, except that FCM III, the general partner of
FCF III, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM III, may be deemed
to have sole power to dispose of these shares.

8 SHARED DISPOSITIVE POWER
See response to row 7.
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON

600,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

1.4%*

12

TYPE OF REPORTING PERSON

PN

* As reported by the Issuer in its Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on August 10, 2017, as of August 3, 2017, the total number of shares of
Common Stock outstanding was 43,756,968.

Follow Cymabay Therapeutics Inc. (NASDAQ:CBAY)











Page 2 of 11